Summary:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled study to investigate the effect of Tirzepatideon the reduction of morbidity and mortality in adults with obesity
Qualified Participants Must:
• Have a BMI greater than 27.0kg
• established CVD, dyslipidemia, tobacco use, hypertension, and/or pre-diabetic
• be able to make entries into a diary device
Qualified Participants May Receive:
Compensation available for participation